Strata Skin Sciences to Delist and Go Dark

The latest update is out from Strata Skin Sciences ( (SSKN) ).

Strata Skin Sciences, Inc. disclosed that after receiving a Nasdaq deficiency notice on August 22, 2025, for failing to meet the $2.5 million minimum stockholders’ equity requirement, it submitted a remediation plan on September 19, 2025, which Nasdaq accepted on October 13, 2025, granting an extension until February 16, 2026. Despite engaging investment banks, filing a confidential registration statement, and meeting with potential investors, the company reported on February 9, 2026, that it could not meet the terms of the extension, prompting Nasdaq on February 10, 2026, to move toward suspending trading and delisting the stock on February 19, 2026, a decision the company will not appeal.

Strata now plans to deregister and terminate its reporting obligations under the Exchange Act by filing with the SEC around February 19 and March 2, 2026, effectively “going dark” to reduce regulatory and administrative costs. Management and the board expect that delisting and going dark will free resources to execute the operating plan, reduce cash burn, and support longer-term value creation, while acknowledging that the move will likely reduce liquidity and make it harder for shareholders to sell their stock, a trade-off they weighed against the costs of remaining listed.

The most recent analyst rating on (SSKN) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.

Spark’s Take on SSKN Stock

According to Spark, TipRanks’ AI Analyst, SSKN is a Neutral.

Overall score reflects weak financial quality (losses, negative cash flow, and elevated leverage) as the primary drag, reinforced by a technically weak longer-term trend. The latest earnings call provides some offset via credible long-term catalysts (expanded reimbursement and litigation-driven market recovery), but near-term revenue pressure and lack of valuation support keep the score below average.

To see Spark’s full report on SSKN stock, click here.

More about Strata Skin Sciences

Strata Skin Sciences, Inc. operates in the medical technology and dermatology sector, focusing on treatments and devices that address skin conditions to improve patient outcomes. The company’s business model is centered on serving dermatology practices and patients, with an emphasis on therapies that enhance quality of life and support long-term clinical care.

Average Trading Volume: 109,240

Technical Sentiment Signal: Sell

Current Market Cap: $6.83M

For a thorough assessment of SSKN stock, go to TipRanks’ Stock Analysis page.